今日药学

肾移植围术期药学监护专家共识

PDF下载

广东省药学会

今日药学 | 专家共识 2026,36(7): 481-491

收起

今日药学 |专家共识 2026 , 36 (7) : 481 -491

肾移植围术期药学监护专家共识

全屏

广东省药学会

作者信息

Expert Consensus on Perioperative Pharmaceutical Care for Kidney Transplantation

Guangdong Pharmaceutical Association

Affiliations

出版时间: 2026-07-25 doi: 10.12048/j.issn.1674-229X.2026.07.001

文章导航

关键词

肾移植围术期 / 药学监护 / 免疫抑制剂 / 围术期并发症 / 个体化用药

Key words

kidney transplantation perioperative period / pharmaceutical care / immunosuppressive agents / perioperative complications / individualized medication

引用本文

广东省药学会. 肾移植围术期药学监护专家共识. 今日药学, 2026 , 36 (7) : 481 -491 . DOI: 10.12048/j.issn.1674-229X.2026.07.001

Guangdong Pharmaceutical Association. Expert Consensus on Perioperative Pharmaceutical Care for Kidney Transplantation[J]. Pharmacy Today, 2026 , 36 (7) : 481 -491 . DOI: 10.12048/j.issn.1674-229X.2026.07.001

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

中华医学会器官移植学分会. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3): 213-226.

[2]

KDIGO. Clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant\, 2009, 9(3): 1-155.

[3]

Brunet M, van Gelder T, Asberg A, et al. Therapeutic drug monitoring of tacrolimus personalized therapy: Second consensus report[J]. Ther Drug Monit, 2019, 41(3): 261-307.

[4]

陈文倩, 张雷, 张弋, 等. 实体器官移植他克莫司个体化治疗专家共识[J]. 中国医院用药评价与分析, 2021, 21(12): 1409-1424.

[5]

Rojas L, Neumann I, Herrero M J, et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies[J]. Pharmacogenomies J, 2015, 15(1): 38-48.

[6]

Woillard J B, Mourad M, Neely M, et al. Tacrolimus updated guidelines through popPK modeling: How to benefit more from CYP3 Apre-emptive genotyping prior to kidney transplantation[J]. Front Pharmacol, 2017, 8: 358.

[7]

Birdwell K A, Decker B, Barbarino J M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing[J]. Clin Pharmacol Ther, 2015, 98(1): 19-24.

[8]

王毅. ABO血型不相容亲属活体肾移植临床诊疗指南(2017版)[J]. 中华移植杂志(电子版), 2017, 11(4): 193-200.

[9]

Yin S, Tan Q, Yang Y, et al. Transplant outcomes of 100 cases of living-donor ABO-incompatible kidney transplantation[J]. Chin Med J (Engl), 2022, 135(19): 2303-2310.

[10]

Tyden G, Donauer J, Wadstrom J, et al. Implementation of a Protocol for ABO-incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations[J]. Transplantation, 2007, 83(9): 1153-1155.

[11]

Chung B H, Lim J U, Kim Y, et al. Impact of the baseline anti-A/B antibody titer on the clinical outcome in ABO-incompatible kidney transplantation[J]. Nephron Clin Pract, 2013, 124(1-2): 79-88.

[12]

Won D, Choe W, Kim H J, et al. Significance of isoagglutinin titer in ABO-incompatible kidney transplantation[J]. J Clin Apher, 2014, 29(5): 243-250.

[13]

Scurt F G, Ewert L, Mertens P R, et al. Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis[J]. Lancet, 2019, 393(10185): 2059-2072.

[14]

Takahashi K, Saito K, Takahara S, et al. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation[J]. Clin Exp Nephrol, 2017, 21(4): 705-713.

[15]

中华医学会器官移植学分会. 中国肾移植受者免疫抑制治疗指南(2016版)[J]. 器官移植, 2016, 7(5): 327-331.

[16]

中国医药生物技术协会移植技术分会, 上海市肾脏移植质控中心专家委员会. 肾移植后期抗体介导排斥反应防治专家共识[J]. 中华医学杂志, 2022, 102(26): 1973-1981.

[17]

朱兰, 王志强, 冯豪, 等. 预致敏受者行死亡捐献供肾肾移植的处理策略及临床效果[J]. 中华医学杂志, 2019, 99(12): 895-900.

[18]

Webster A C, Ruster L P, Mcgee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients[J]. Cochrane Database Syst Rev, 2010, 2010(1): CD003897.

[19]

Kiberd B A, Lawen J, Fraser A D, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation[J]. American Journal of Transplantation Official Journal of the American Society of Transplantation & the American Society of Transplant Surgeons, 2015, 4(7): 1079-1083.

[20]

中华医学会器官移植学分会, 中国医师协会器官移植医师分会, 上海医药行业协会, 等. 中国肝、肾移植受者霉酚酸类药物应用专家共识(2023版)[J]. 上海医药, 2023, 44(19): 3-19.

[21]

广东省药学会. 肾移植患者免疫抑制剂长期管理医药专家共识[J]. 今日药学, 2022, 32(11): 801-816.

[22]

Ju M K, Huh K H, Park K T, et al. Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety[J]. Transplant Proc, 2013, 45(4): 1481-1486.

[23]

中华医学会器官移植学分会. 中国肾移植受者哺乳动物雷帕霉素靶蛋白抑制剂临床应用专家共识[J]. 中华器官移植杂志, 2017, 38(7): 430-435.

[24]

Yuan X, Chen C, Zheng Y, et al. Conversion from mycophenolates to mizoribine is associated with lower BK virus load in kidney transplant recipients: a prospective study[J]. Transplant Proc, 2018, 50(10): 3356-3360.

[25]

Li P, Cheng D, Wen J, et al. Conversion from mycophenolate mofetil to mizoribine in the early stages of BK polyomavirus infection could improve kidney allograft prognosis: a single-center study from China[J]. BMC Nephrol, 2021, 22(1): 328.

[26]

陈晨岳, 慧杰, 黄晓晖, 等. 肾移植术后咪唑立宾疗效和不良反应与其浓度、剂量和用药时长的相关性研究[J]. 实用药物与临床, 2021, 24(5): 405-440.

[27]

李佳, 孙萍萍, 傅茜, 等. 高效液相色谱法与酶放大免疫测定法检测肾移植后血麦考酚酸浓度的比较[J]. 中华器官移植杂志, 2014, 35(9): 528-532.

[28]

Weber L T, Shipkova M, Armstrong V W, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy[J]. Clin Chem, 2002, 48(3): 517-525.

[29]

中华医学会器官移植学分会. 肾移植排斥反应临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(5): 505-512.

[30]

Zhang R. Clinical management of kidney allograft dysfunction[J]. Open Journal of Organ Transplant Surgery, 2014, 4(2): 7-14.

[31]

Jamalbamoulid, Oliverstaeck, Thomascrépin, et al. Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects[J]. Nephrology dialysis transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association, 2017, (10): 32.

[32]

Lefaucheur C, Louis K, Morris A B, et al. Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document[J]. Am J Transplant, 2023, 23(1): 115-132.

[33]

Rodriguez-Ramirez S, Al Jurdi A, Konvalinka A, et al. Antibody-mediated rejection: prevention monitoring and treatment dilemmas[J]. Curr Opin Organ Transplant, 2022, 27(5): 405-414.

[34]

Sethi S, Jordan S C. Novel therapies for treatment of antibody-mediated rejection of the kidney[J]. Curr Opin Organ Transplant, 2023, 28(1): 29-35.

[35]

卢晓阳, 吴建永. 中国300种疾病药学服务标准与路径-肾移植分册[M]. 北京: 人民卫生出版社, 2022.

[36]

Abbo L M, Grossi P A, Ast Id Community of Practice. Surgical site infections: guidelines from theAmerican Society of Transplantation Infectious DiseasesCommunity of Practice[J]. Clin Transplant, 2019, 33(9): e13589.

[37]

Zhang W, Wang W, Kang M, et al. Bacterial andfungal infections after liver transplantation: microbialepidemiology risk factors for infection and death with infection[J]. Ann Transplant, 2020, 25: e921591.

[38]

中华医学会器官移植学分会, 中华预防医学会医院感染控制学分会, 复旦大学华山医院抗生素研究所. 中国实体器官移植供者来源感染防控专家共识(2018版)[J]. 中华器官移植杂志, 2018, 39(1): 41-52.

[39]

中华医学会器官移植学分会. 器官移植供者来源性感染诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(4): 369-375.

[40]

Fields A C, Pradarelli J C, Itani K M F. Preventingsurgical site infections: looking beyond the current guidelines[J]. JAMA, 2020, 323(11): 1087-1088.

[41]

刘炎忠, 柏宏伟, 钱叶勇, 等. DCD时代肾移植术后耐碳青霉烯类肺炎克雷伯菌感染的治疗经验总结[J]. 器官移植, 2020, 11(1): 76-81.

[42]

中国医师协会器官移植医师协会, 中华医学会器官移植学分会. 中国实体器官移植手术部位感染管理专家共识(2022版)[J]. 器官移植, 2023, 14(1): 13-23.

[43]

Ye Q F, Zhou W, Wan Q Q. Donor-derived infections among Chinese donation after cardiac death liver recipientsf[J]. World Gastroenterol, 2017, 23(31): 5809-5816.

[44]

Chen C, Zhou I. Organ donation and Yuan X, transplantation from donors with systemic infection: a single center experience[J]. Transplant Proc, 2016, 48(7): 2454-2457.

[45]

杨志坚, 张诗辰, 王彦峰, 等. 170例供者感染流行病学分布及肾移植供者来源性感染危险因素分析[J]. 中华器官移植杂志, 2019, 40(9): 533-538.

[46]

中华医学会器官移植学分会. 中国肾脏移植供者来源性感染临床诊疗指南(2023版)[J]. 中华器官移植杂志, 2024, 45(4): 269-282.

[47]

范鹏飞, 王清平, 王洪海, 等. 公民逝世后器官捐献供者感染流行病学分布及主要病原菌耐药性分析[J]. 器官移植, 2022, 13(2): 225-231.

[48]

中华医学会器官移植学分会. 器官移植受者侵袭性真菌病临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(3): 227-236.

[49]

中华医学会器官移植学分会, 中国肾脏移植受者细菌感染临床诊疗指南(2023版)[J]. 中华器官移植杂志, 2024, 45(9): 582-593.

[50]

中华医学会器官移植学分会. 器官移植术后耐药菌感染诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(4): 1674-7445.

[51]

中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识[J]. 中华结核和呼吸杂志, 2018, 41(6): 409-446.

[52]

中华医学会器官移植学分会. 中国实体器官移植术后高血压诊疗规范(2019版)[J]. 器官移植, 2019, 10(2): 114-121.

[53]

李黔生, 曹伟, 靳凤烁. 临床肾移植围手术期治疗学[M]. 北京: 军事医学科学出版社, 2006: 152.

[54]

中华医学会. 临床技术操作规范-器官移植学分册[M]. 北京: 人民军医出版社, 2008: 17.

[55]

Walsh M, Devereaux P J, Garg A X, et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension[J]. Anesthesiology, 2013, 119(3): 507-515.

[56]

李志雄, 唐礼功, 潘铁军, 等. 低血压肾移植受者围手术期持续应用多巴胺48例分析[J]. 中国药师, 2009, 12(7): 936-938.

[57]

张凯璐. 去甲肾上腺素对肾移植术中血流动力学及术后肾功能的影响[D]. 昆明: 昆明医科大学, 2019.

[58]

Whelton P K, Carey R M, Aronow W S, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention Detection Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2018, 71(19): 127-248.

[59]

Cross N B, Webster A C, Masson P, et al. Antihypertensive treatment for kidney transplant recipients[J]. Cochrane Database Syst Rev, 2009(3): CD003598.

[60]

Clase C M, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes[J]. Kidney Int, 2017, 91(3): 683-690.

[61]

国家卫生计生委合理用药专家委员会, 中国医师协会高血压专业委员会. 高血压合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2017, 9(7): 28-126.

[62]

中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志, 2024, 32(7): 603-700.

[63]

Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects[J]. Ann Rheum Dis, 2009, 68(7): 1119-1124.

[64]

Redmon J B, Olson L K, Armstrong M B, et al. Effects of tacrolimus (FK506) on hymaninsulin gene expression insulin mRNA levels and insulin secretion in HlT-T15 cells[J]. ClinInvest, 1996, 98(12): 2786-2793.

[65]

Vincenti F, Friman S, Scheuermann E, et al. Results of an international randomizedtrial comparing glucose metabolism disorders and outcome with cyclosporine versustacrolimus[J]. Am J Transplant, 2007, 7(6): 1506-1514.

[66]

中国医师协会内分泌代谢科医师分会, 中国住院患者血糖管理专家组. 中国住院患者血糖管理共识[J]. 中华内分泌代谢杂志, 2017, 33(1): 1-9.

[67]

广东省药学会. 围手术期血糖管理医-药专家共识[J]. 今日药学, 2018, 28(2): 73-83.

[68]

中华医学会器官移植学分会. 中国移植后糖尿病诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(1): 1-9.

[69]

吴钿生, 周洪彬, 黄焕森. 目标导向液体治疗对肾移植术后早期功能恢复及并发症的影响[J]. 临床麻醉学杂志, 2020, 36(10): 980-983.

[70]

Jia H, Huang F, Zhang X, et al. Early perioperative fluid overload is associated with adverse outcomes in deceased donor kidney transplantation[J]. Transplant Int, 2021, 34(10): 1862-1874.

[71]

Collange O, Tacquard C, Oulehri W, et al. Hemodynamic management during kidney transplantation: afrench survey[J]. Transplantat Proc, 2021, 53(5): 1450-1453.

[72]

赵玉沛, 杨尹默, 楼文晖, 等. 外科病人围手术期液体治疗专家共识(2015)[J]. 中国实用外科杂志2015 35(9): 960-966.

[73]

汪博, 杜瑞妮, 阳婷婷, 等. 肾移植围手术期容量管理研究进展[J]. 肾脏病与透析肾移植杂志, 2020, 29(5): 489-493.

[74]

Wagener G, Bezinover D, Wang C, et al. Fluid Management During Kidney Transplantation: A Consensus Statement of the Committee on Transplant Anesthesia of the American Society of Anesthesiologists[J]. Transplantation, 2021, 105(8): 1677-1684.

[75]

Breda A, Budde K, Figueiredo A, et al. EAU guidelines on renal transplantation[J]. Netherlands: EAU Guidelines Office, 2020: 278-279.

[76]

Zarychanski R, Abou-Setta A M, Turgeon A F, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis[J]. JAMA, 2013, 309(7): 678-688.

[77]

疏树华, 柴小青, 李传耀, 等. 羟乙基淀粉130/0.4对活体肾移植患者肾功能的影响[J]. 临床麻醉学杂志, 2012, 28(8): 742-744.

[78]

Yoshid A T, Yanishi M, Nakamoto T, et al. Successful treatment of transplant renal artery thrombosis with systemic infusion of recom-binant-tissueplasminogen activator after renal transplant[J]. Exp Clin Transplant, 2017, 15(5): 571-573.

[79]

Harraz A M, Shokeir A A, Soliman S A, et al. Salvage of graffits with vascular thrombose during living donor renal allotransferation: a crítico analysis of successful outcome[J]. Int J Urol, 2014, 21(10): 999-1004.

[80]

Lysakowski S, Druck G C, Weisheimer R R, et al. Pediatric kidney transplantation: outcomes with under and over 6-year-old donors[J]. J Pediatr (Rio J), 2024, 100(1): 67-73.

[81]

Verhave J C, Tagalakis V, Suissa S, et al. The risk of thromboembolic events in kidney transplant patients[J]. Kidney Int, 2014, 85(6): 1454-1460.

[82]

中华医学会器官移植学分会. 肾移植围手术期处理操作规范(2019版)[J]. 器官移植, 2019, 10(5): 489-493.

[83]

中华医学会器官移植学分会. 中国肾脏移植长期健康管理指南[J]. 中华器官移植杂志, 2024, 45(5): 283-298.

2026年第36卷第7期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.12048/j.issn.1674-229X.2026.07.001

首发时间：2026-10-27
出版时间：2026-07-25

补充材料

相关文章

文章信息

作者

出版历史

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/jryx/CN/10.12048/j.issn.1674-229X.2026.07.001

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT